Services
Company
Legal and Governance
Publication Library / Publications
Real-world effectiveness of brentuximab vedotin versus physicians’ choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany
Abstract
This retrospective study compared effectiveness of (brentuximab vedotin) BV to other chemotherapies in patients with rrHL following an autologous stem cell transplant (ASCT). Data originated from a medical chart review of patients treated in real-world clinical settings at 50 sites in the United Kingdom and Germany. Inverse probability of treatment weights based on propensity scores were used to adjust for differences in baseline characteristics between treatment groups. Among 312 rrHL patients included, 196 received BV and 116 received physicians’ choice chemotherapy. Median PFS was significantly longer (27.0 months vs. 13.4 months; p?=?.0144) and 12-month OS survival greater (78.1% vs. 65.9%; p?=?.0129) with BV compared to chemotherapy. Documented adverse events included leukopenia (12.8%) and peripheral neuropathy (8.7%) for BV and leukopenia (12.1%), anemia (5.2%) and diarrhea (5.2%) for chemotherapy. In this real-world study, rrHL patients treated for relapse after ASCT with BV had longer median PFS and 12-month OS than patients receiving chemotherapy.
Authors
E A Zagadailov, S Corman, V Chirikov, C Johnson, C Macahilig, B Seal, MR Dalal, P J Brockelmann, T Llidge
Journal
Leukemia & Lymphoma
Therapeutic Area
Oncology
Center of Excellence
Real-world Evidence & Data Analytics
Year
2017
Read full article